Okyo Pharma LTD ADR reports a Return on Equity (ROE) of -105.41%.

What is OKYO's dividend yield?

Okyo Pharma LTD ADR offers a dividend yield of 0.00%.

What is OKYO's Quality Score?

Our AI rates OKYO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy OKYO?

Our AI Timing Score for OKYO is 63 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does OKYO belong to?

Okyo Pharma LTD ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Okyo Pharma LTD ADR (OKYO) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-06-30)

OKYO AI Analysis Summary

Our AI summary for OKYO: Okyo Pharma LTD ADR (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -105.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 63/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

OKYO

Okyo Pharma LTD ADR

US:NASDAQ STOCK Healthcare >> Biotechnology News 83

USD 1.57

-0.07 (-4.27%) Day Change

Watchlist Portfolio Compare Chart

0.70

D/E

-105.4%

ROE

-62.0%

ROA

0.00%

Div Yield

OKYO PHARMA LTD ADR
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 1.57 Price -0.07 (-4.27%) Day Change	NEWS SCORE: 83

OKYO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	83
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.57
PBV / Sector	6.98 / 44,105.10
Earning Per Share	-0.24

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.21 M GREAT
Average 1W Daily Value	0.06 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	N/A / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-61.99 / 185,260.64
ROA Average (%) / Sector	-315.87 / 36,684.64
ROA Change Average (%) / Sector	54.60 / 422,221.42 GREAT
ROE (%) / Sector	-105.41 / 243,761.81
ROE Average (%) / Sector	167.88 / 48,758.38 GREAT
ROE Change Average (%) / Sector	-66.59 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:27
Symbol	OKYO
Name	OKYO PHARMA LTD ADR
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	52.48 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	86.07 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 14/15 Conduit St, London, United Kingdom, W1S 2XJ

Phone: 44 20 7495 2379

Website: https://okyopharma.com

Sector: Healthcare >> Biotechnology

Description: OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.